EffRx Pharmaceuticals SA is proud to announce that it will participate in the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Florence, Italy, from 23 to 26 March 2017. The WCO-IOF-ESCEO Congress, as it is also known, is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue for EffRx to showcase its flagship product Binosto, the world’s first and only buffered soluble alendronate for the treatment of postmenopausal osteoporosis. Medical professionals from around the world will be able to learn more about Binosto and its exciting properties at the Binosto booth in the exhibition area (booth #21).
EffRx Pharmaceuticals SA is equally thrilled to inform that it will present the latest safety data on Binosto at the WCO-IOF-ESCEO Congress. The data will be presented in the poster area on 24 March 2017, from 14:00 to 15:00 (poster #589).
Please join EffRx at the WCO-IOF-ESCEO Congress in Florence!
